These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35542998)

  • 1. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 3. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
    Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
    J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.
    Papp KV; Rentz DM; Orlovsky I; Sperling RA; Mormino EC
    Alzheimers Dement (N Y); 2017 Nov; 3(4):668-677. PubMed ID: 29264389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Data-Driven Cognitive Composite Sensitive to Amyloid-β for Preclinical Alzheimer's Disease.
    Liu S; Maruff P; Fedyashov V; Masters CL; Goudey B
    J Alzheimers Dis; 2024; 101(3):889-899. PubMed ID: 39269831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study.
    Papp KV; Maruff P; Rentz DM; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):846-856. PubMed ID: 39044493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.
    Sperling R; Henley D; Aisen PS; Raman R; Donohue MC; Ernstrom K; Rafii MS; Streffer J; Shi Y; Karcher K; Raghavan N; Tymofyeyev Y; Bogert J; Brashear HR; Novak G; Thipphawong J; Saad ZS; Kolb H; Rofael H; Sanga P; Romano G
    JAMA Neurol; 2021 Mar; 78(3):293-301. PubMed ID: 33464300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial.
    Papp KV; Rentz DM; Maruff P; Sun CK; Raman R; Donohue MC; Schembri A; Stark C; Yassa MA; Wessels AM; Yaari R; Holdridge KC; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2021; 8(1):59-67. PubMed ID: 33336226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
    Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.
    Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA
    Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
    Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
    Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study.
    Ruthirakuhan M; Wood Alexander M; Cogo-Moreira H; Robinson T; Amariglio R; Buckley RF; Sperling RA; Swardfager W; Black SE; Rabin JS
    J Prev Alzheimers Dis; 2024; 11(1):48-55. PubMed ID: 38230716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
    Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults.
    Aslanyan V; Ortega N; Fenton L; Harrison TM; Raman R; Mack WJ; Pa J
    Neuroimage Clin; 2023; 39():103460. PubMed ID: 37379733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.
    Lim YY; Snyder PJ; Pietrzak RH; Ukiqi A; Villemagne VL; Ames D; Salvado O; Bourgeat P; Martins RN; Masters CL; Rowe CC; Maruff P
    Alzheimers Dement (Amst); 2016; 2():19-26. PubMed ID: 27239532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
    Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
    Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.
    Amariglio RE; Grill JD; Rentz DM; Marshall GA; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):838-845. PubMed ID: 39044492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study.
    Cumplido-Mayoral I; Brugulat-Serrat A; Sánchez-Benavides G; González-Escalante A; Anastasi F; Milà-Alomà M; López-Martos D; Akinci M; Falcón C; Shekari M; Cacciaglia R; Arenaza-Urquijo EM; Minguillón C; Fauria K; Molinuevo JL; Suárez-Calvet M; Grau-Rivera O; Vilaplana V; Gispert JD;
    Lancet Healthy Longev; 2024 Apr; 5(4):e276-e286. PubMed ID: 38555920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.